Close

taxonomy for: BD Exec Training

Biotechnology Entrepreneurship Boot Camp

The fifteenth annual Biotechnology Entrepreneurship Boot Camp is an intensive, two-day program that walks you through the necessary steps and gives you the skills to transform technology and invention into a viable company. Since its debut in 2005, the Boot Camp has evolved to address a broad range of issues faced by entrepreneurs from the managerial, scientific and academic communities. You develop the insight and energy required for entrepreneurial success as you learn to:

  • Think strategically in selecting and managing projects
  • Plan for expeditious and cost-effective management
  • Understand the requirements of all the involved stakeholders
  • Oversee the essential components of the commercialization process

Each year, faculty from the event’s host region bring fresh insights to the program, while a core faculty returns to present material that has proven effective throughout the years.

View the 2018 Agenda

Thank You to Our 2018 Sponsor: 

Conferences and Events: 

Negotiations and Strategic Decision Making Course

Negotiations and Strategic Decision Making
 

The Negotiations and Strategic Decision Making: Learnings from Game Theory and BD Practice Course is designed for executives, and business development professionals interested in enhancing their skills in negotiations, influencing, decision making and game theory. The uniqueness of this workshop is to leverage the combination of these skills to allow you to better understand how your counterpart in the negotiations might assess potential strategic options. You will learn not only to anticipate but also to plan strategically ahead by making use of insights from game theory, with the aim to improve the outcome of your negotiations. The learnings from game theory will be applied to real-life pharma/biotech negotiation cases. This training will help participants to sharpen their business development skills by increasing the speed and quality of their decision making and enhance negotiation skills.

The course was first part of an ASAP global conference last fall in Boston. A few quotes from the attendees: "…course content is strong, loved the variety of real life practical cases, practicing through exercises, well put together concise slides, liked the two-instructor approach…academic and industry, loved the topic-tying game theory, to negotiations, to decision making, to influencing."

Click to Download Sample Course Slides

2018 Negotiations and Strategic Decision Making Faculty:

Harm-Jan Borgeld, CSAP, PhD, Head Alliance Management, Merck KGaA

Harm Jan Borgeld

Harm-Jan Borgeld is leading the alliance management department at Merck KGaA. The department is responsible for the commercial, development, research, and selected regional alliances. Before heading the alliance management department, he was leading a project team that worked on developing a novel immunotherapy to treat cancer. He started his work at Merck in the licensing and business development department. Prior to Merck, he was responsible for the business development activities of the Japanese firm, Kyorin Pharmaceuticals, in Europe. He received his MBA from the Rotterdam School of Management, the Netherlands / Haas Business School, US, and his PhD from the Faculty of Medicine, University of Nagoya, Japan, and graduated from the Wageningen University, the Netherlands.

Stefanie Schubert, CA-AM, PhD, Professor of Economics, SRH University Heidelberg

Sarah S

Stefanie Schubert is Professor of Economics at SRH University Heidelberg. Previously, she was assistant professor of organization theory and management at WHU-Otto Beisheim School of Management (Koblenz & Düsseldorf). Her expertise includes strategic decision making, managerial economics, and strategic alliances and networks. In addition, Stefanie is consultant for strategic management with a particular focus on conceptual strategy development and strategic behavior. She has published in distinguished international journals, such as the Journal of Health Economics, Applied Economics and Small Business Economics. She received her PhD from University Duisburg-Essen and graduated from Heidelberg University.

Topics Covered:

  • Game theory (the science of strategic decision making)

  • Negotiations; including:
    • Three phases of negotiations
    • First and second offer strategies
    • Group negotiations (in class exercise)
    • How to behave with emotional negotiators.
    • Multiple Equivalent Simultaneous Offers
  • Decision making
    • How do CEOs decide?
    • Parallel option assessment
  • Case studies

  • Influencing
    • How to weaken your opponent’s strategic moves

Who should attend?

The workshop is designed for business development professionals who have most likely served as part of a business development or licensing team, but are now preparing to move to a senior manager level role within their organization. Highly experienced business development professionals benefit by getting an update on the latest techniques, revised rules/regulations and honing deal-making skills.

  • Business Development & Licensing professionals
  • Alliance Management professionals
  • R&D personnel who have significant interaction with business development
  • Intellectual property personnel involved in the licensing process
  • Biotech – Senior Management
  • Professionals who are new to business development and licensing or who have limited deal experience

2018 Agenda

Sunday, June 3, 2018

9:00 AM - 9:30 AM Welcome Remarks 
9:30 AM - 10:45 AM PART 1: Strategic Decision MakingAssessing options, analyzing choices and outcomes
10:45 AM - 11:00 AM Break
11:00 AM - 12:30 PM PART 2: Negotiations—Improving the outcome
12:30 PM - 1:15 PM Lunch
1:15 PM - 2:45 PM PART 2: Negotiations, cont.
PART 3: Influencing—Driving without steering
2:45 PM - 3:00 PM Break
3:00 PM - 4:00 PM PART 3: Influencing, cont. 
4:00 PM - 4:30 PM PART 4:    Lessons Learned—Feedback and Closing Remarks

 

Conferences and Events: 

Product & Company Valuation Program

 

 

2018 Product and Company Valuation Instructor:

Patrik Frei, CEO & Founder, Venture Valuation

Patrik Frei

Patrik Frei is a leading expert in the valuation of life science companies and his combination of knowledge and experience allows him to speak with authority on the subject. Patrik wrote the first book on the valuation of high-growth companies and holds a Ph.D in the field. His company, Venture Valuation, has completed over 400 independent company and product valuations.

 

Friday, June 1, 2018

10:00 AM- 10:15 AM Welcome
10:15 AM - 11:00 AM Introduction to Valuation: What – Why - When
11:00 AM - 11:30 AM How to Assess a Company Prior to Valuation
11:30 AM - 11:45 AM Break
11:45 AM - 1:30 PM Company Valuation
1:30 PM - 2:15 PM Lunch
2:15 PM - 4:45 PM Product Valuation & Deal Structuring
4:45 PM - 5:00 PM Final Discussion & Wrap-up

 

*Note: Schedule subject to change

Conferences and Events: 
H1: 
Program

Advanced Business Development Program


2018 Advanced Business Development Faculty:

Debbie Allen, Senior Vice President Business Development, arGEN-X

Debbie Allen

Debbie Allen has been active in the antibody engineering field since the 1980s. She brings to argenx more than 30 years of corporate and business development experience with small and large biotech companies focused on biopharmaceuticals. Dr. Allen is an inventor of HUMIRA® (adalimumab). She established her business development career at Cambridge Antibody Technology (acquired by Astra Zeneca), where she had management responsibility for technology, intellectual property and product out-licensing, corporate equity, co-development and cross-license agreements. She was responsible for the 1999 license agreement with Human Genome Sciences that led to the discovery of the antibody drug BENLYSTA®(belimumab), now approved for the treatment of systemic lupus erythematosus.

Prior to joining argenx, Dr. Allen acted as an independent consultant to around 25 emerging biotech companies, providing strategic management and business development support.

Joe Dillon, PhD, MBA, President, Dillon Capital Strategies

Dillon

Joseph S. Dillon, Ph.D., MBA, is President & CEO of SynerPhysics, Inc. and President of Dillon Capital Strategies, the strategy and business analytics advisory arm of SynerPhysics. Dr. Dillon is a seasoned pharmaceutical executive with over 20 years of experience. He has extensive experience in global pharmaceutical business development, planning and analysis, corporate finance, M&A, licensing, and technology valuations. Dr. Dillon has screened thousands of opportunities, valued over 300 deals and has been involved in over 40 closed transactions over the course of his career. Since forming Dillon Capital Strategies, Dr. Dillon has consulted dozens of companies, including holding the CEO position at BioPact, a medical nanotechnology company, during its developmental stage. Prior to that, Dr. Dillon held senior positions in pharmaceutical management consulting firms, most significantly as Senior Vice President, Head of Corporate Development Services and Valuations for The Mattson Jack Group (now Kantar Health). Other previous positions include CEO, President, and Director of The Pharmaceutical Development Center, a pharmaceutical developer and manufacturer; Executive Vice President and CFO of Vail Banks Inc., a multi-bank holding company; CFO and Treasurer of Oread Inc., a contract pharmaceutical developer and manufacturer; and corporate positions with predecessor companies of Sanofi. Dr. Dillon is Past-Chairperson of the Licensing Executive Society Life Sciences Sector. He is a veteran speaker at BIO, LES, WBR, EBD, and other prominent industry organization events. Dr. Dillon holds a Ph.D. in Metaphysical Sciences, an M.B.A. in International Finance and a bachelors in Finance.

Kenneth Krisko, Partner, Cooley LLP

Kenneth Krisko

Kenneth Krisko is a partner in the Cooley Business department. He joined the Firm in 2000 and splits his time between the Reston and Boston offices.

Mr. Krisko's practice focuses on the representation of public and private life sciences companies in a broad range of commercial and corporate finance matters. He advises clients regularly with respect to complex commercial transactions designed to maximize the value of pharmaceutical products and technology assets, including technology licenses and acquisitions, research and development collaborations, distribution and manufacturing agreements, and profit-sharing and co-promotion arrangements.

Mr. Krisko also regularly counsels clients on a wide array of corporate and securities matters, including spin-outs, private financing, mergers and acquisitions, public offerings and corporate governance. He works closely with his clients to understand each client's business and strategic objectives and to structure and negotiate transactions to meet those objectives.

Mr. Krisko has been a guest speaker on strategic partnering and corporate issues affecting life sciences companies at various conferences. Mr. Krisko also is an Adjunct Professor of Law at the Georgetown University Law Center where he teaches a course on emerging company legal issues and venture capital finance.

Mr. Krisko received a JD from the University of Virginia School of Law in 1995, where he was a member of the Virginia Law Review. Mr. Krisko received a BS in Aerospace and Ocean Engineering from Virginia Tech in 1987.

Prior to joining Cooley, Mr. Krisko was an associate with Wiley, Rein & Fielding in Washington, DC  Prior to attending law school, Mr. Krisko worked as an engineer for the Department of the Navy.

Mr. Krisko is admitted to practice in the Commonwealth of Virginia, the District of Columbia. He is not admitted to practice in Massachusetts.

Lesley Stolz, PhD, Head of JLABS California

Lesley Stolz

Lesley is Senior Director of Transactions at Johnson & Johnson Innovation, California. Lesley has been working in corporate and business development roles for the last 17 years for companies that are both technology platform and therapeutics focused; Her most recent executive positions have been with BioTime, a publicly traded stem cell technology and therapeutic company, and Sutro Biopharma, a platform technology company working in cell-free protein synthesis. Prior to Sutro, Lesley served in BD positions for a number of biotech companies in the U.S.. and Europe. Lesley received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School’s Department of Biochemistry and Molecular Pharmacology.


Friday, June 1, 2018: Valuation and Deal Structuring Skills

8:00 AM - 8:30 AM Registration Open & Breakfast
8:30 AM - 9:45 AM Valuation and Deals Structuring Concepts and Trends
9:45 AM - 10:00 AM Refreshment Break
10:00 AM - 11:00 AM Advanced Valuation and Decision Analysis
11:00 AM - 12:30 PM   Case Study Work
12:30 PM - 1:30 PM   Lunch
1:30 PM - 2:30 PM Market Models, Competition, Cash Flow Estimates
2:30 PM -2:45 PM Refreshment Break
2:45 PM - 4:00 PM Case Study Work & Break Out Sessions
4:00 PM - 5:00 PM Value Distribution and Terms
5:30 PM - 7:00 PM Networking Reception

 

Saturday, June 2, 2018: Negotiation Strategies and Intellectual Property

8:00 AM -8:30 AM Breakfast
8:30 AM - 9:45 AM Negotiation Preparation
9:45 AM - 10:45 AM Case Study Work
Refreshments Available
10:45 AM - 11:45 AM Managing the Process and Influence Strategies
11:45 AM - 12:30 PM Case Study Work
12:30 PM - 1:30 PM Lunch
1:30 PM -3:00 PM Types of IP, Freedom to Operate, Issues in Due Diligence
3:00 PM - 4:15 PM Case Study Work 
Refreshments Available
4:15 PM - 5:00 PM Creating a Protection Timeline, Research Exemption, Competition Law
5:00 PM - 5:45 PM Case Study Work

 

Sunday, June 3, 2018: Contracts

8:00 AM - 8:30 AM   Breakfast
8:30 AM - 9:45 AM Key Concepts and Building Blocks of a Block Buster Deal
9:45 AM - 10:30 AM Select Topics of Advanced Deal Structures
10:30 AM - 10:45 AM Refreshment Break
10:45 AM - 11:45 AM Trap Doors, Dead Ends, and other Do's and Don'ts
11:45 AM - 12:30 PM Current Trends in Licensing Deals
12:30 PM -3:00 PM Working Lunch and Case Study Completion
3:00 PM - 3:45 PM Case Study Review


*Note: Schedule Subject to change

Conferences and Events: 
H1: 
Program

Business Development Fundamentals Course

Since 2003, the Business Development Fundamentals Course has been offered as a joint collaboration between the Biotechnology Innovation Organization, our distinguished faculty, and supporting organizations. The course is introductory-level and designed for professionals new to the life sciences business development field, or for individuals with some experience and who are interested in updating their knowledge and professional skills. Many participants who may already have some experience in licensing or business development will take this course as a refresher.

2018 Business Development Fundamentals Faculty:

Anjan Aralihalli, Chief Business Officer, GLyPharma Therapeutic; Venture Partner, CTI Life Sciences Fund II

Anjan Aralihalli

Anjan or "AJ" Aralihalli is currently Chief Business Officer of GLyPharma Therapeutic, a Canadian biotechnology company focused on rare GI disorders.  He is also a Venture Partner at CTI Life Sciences, a leading Canadian venture fund and is a member of a NYC based angel investment group called Mid-Atlantic Bio Angels (MABA).  AJ is also a corporate fundraiser for two ALS charities, Wings Over Wall Street (a division of the Muscular Dystrophy Association) and The Robert Packard Center for ALS Research at Johns Hopkins University.

Previously, he worked at a variety of biotechs and pharma companies including Neurochem, Abbott, Sanofi, Shionogi and ActoGeniX.  He has 20+ years of international experience across a number of functions including investor relations, corporate development, venture and angel financing, in & out-licensing, strategic alliances, alliance management, new product development, sales, marketing, & clinical trial management.  

He received his BSc from Concordia University, MBA from Queen's University (both in Canada) and is currently completing his MSc at Johns Hopkins University.

Mark Cooper, Principal, Faber Daeufer & Itrato PC

Mark Cooper

Mark is an accomplished and versatile corporate and transactional attorney in the life sciences industry with over 25 years of experience. Mark has extensive experience advising, structuring, drafting and negotiating strategic transactions (research, development and commercialization) at all stages of the product lifecycle, most recently at Faber Daeufer & Itrato PC and before, in-house at Pfizer.

During his 17 years with Pfizer, Mark structured and negotiated a wide range of complex research collaborations, IP licenses, development funding agreements and commercial stage co-promotion agreements. His experience with transactions at all phases of the pharmaceutical product life cycle has given him a deep understanding of business strategies and issues, including those involved with emerging technologies like gene therapy and RNAi.

Kathleen Denis, PhD, CLP-Founding Director, Office of Technology Transfer, The Rockefeller University

Kathleen Davis

Kathleen A. Denis is a consultant specializing in the management of intellectual assets in the life sciences, working with academic and industry clients to manage intellectual property portfolios, evaluate new technologies, market and license technologies and start new technology-based businesses. Dr. Denis is active in numerous professional organizations and speaks frequently about early stage technology evaluation, formation of start-up companies, conflict of interest and other issues of academic technology transfer. She currently serves on the boards of the AUTM Foundation, ELabNYC, and Militia Hill Ventures.

Dr. Denis was the Founding Director of the Office of Technology Transfer at The Rockefeller University, a premier biomedical research institution located in New York City, where she spent almost 18 years managing the intellectual property of their elite researchers. She is a Past President of the Licensing Executives Society USA/Canada (LES), and has served on the boards of the Association of University Technology Managers (AUTM) and the Pennsylvania Biotechnology Association. She is a Certified Licensing Professional, a former Chair of the Board of Governors of Certified Licensing Professionals, Inc. and a Registered Technology Transfer Professional (RTTP).

From 1995 through 1998 Dr. Denis was Vice President, Technology Development at Allegheny Health, Education and Research Foundation. She was a Director at the University of Pennsylvania Center for Technology Transfer from 1991 to 1995, where she managed a large portfolio of biotechnology and pharmaceutical related technologies. Previously, she was an investigator at the Molecular Biology Institute at UCLA for eight years, and a Senior Scientist at Specialty Laboratories, Inc. She has over thirty scientific publications.

Dr. Denis holds a Ph.D. in immunology from the University of Pennsylvania, an M.A. in Human Genetics from University of Texas Medical Branch at Galveston and an undergraduate degree in genetics from Cornell University.

Philippe Nore, Managing Partner, Palo Alto BioVentures

Phillippe Nore

Philippe Nore is the Managing Partner of Palo Alto BioVentures, a boutique strategy and business development consulting firm focused on life sciences.  He is an experienced consultant, entrepreneur and business executive specialized in clinical diagnostics, life science tools and therapeutics. Before founding Palo Alto Bio Ventures, he co-founded and led as CEO MiNDERA, an innovative MedTech company developing Next-Gen Skin Diagnostics and Analytics.

Previously Philippe was Senior International Business Leader at Roche Diagnostics. He was responsible for the development and commercialization of the Ventana Digital Pathology products (hardware, software, algorithms to score assays) in the cancer diagnostics market, including global P&L responsibility. During his tenure at Roche he has successfully launched several FDA-approved products.

Prior to that, he was a Senior Engagement Manager at L.E.K. Consulting where he worked with CEOs of small and midsize biotech and life sciences companies. Earlier, he worked at Life Technologies where he headed Strategic Planning and Business Development for the DNA Sequencing business Unit and led the Next-Generation Sequencing taskforce. He also spent 7 years at Bain & Company where he consulted for Fortune 500 companies. Philippe holds a MSc. in chemistry from ESPCI (Paris) and an MBA from the Wharton School where he graduated as a Palmer Scholar.

Veronique Riethuisen, Vice President of R&D, Business Development, Takeda

Veronique Riethuisen

Veronique Riethuisen, a native of Belgium, has more than 25 years of deal making experience across the healthcare spectrum from the pharmaceutical, biotech, diagnostics, medical devices, e-health and academics. She has closed an array of early and late stage deals, both on the buy-side and the sell-side. She's also successfully managed many deal teams both in the US and internationally.

Veronique is currently Vice President of R&D BD at Takeda, responsible with her team for establishing partnerships to support GI and Regenerative Medicine as well as overseeing all out-bound transactions for Takeda's R&D assets. Veronique also represents Takeda on Portal Instruments’ Board of Directors.

Prior to Takeda, Veronique led the CNS and Biosimilars business development activities at Teva where she successfully landed their US partnership with Celltrion. Prior to Teva, Veronique was for almost 10 years part of the WW BD group at Pfizer Inc. where she focused on late stage partnering opportunities mainly in cardiovascular/metabolic diseases, primary care and mobile health. She also served as a board observer representing Pfizer on Aviir and iCardiac's Board of Directors. Prior to Pfizer, Veronique was at Bristol-Myers Squibb where she primarily managed the global alliance with Medarex for ipilimumab. Prior to BMS, Veronique headed business development efforts for two startups in the field of proteomic biomarkers and pharmacogenomics services.

Veronique's career started at Monsanto where for 10 years she held a variety of M&A, Business Development and project management roles in Europe and in the US., in biologics and life science businesses.

Veronique received her Bachelor and Master degrees in Applied Economics from the University of Brussels (ULB), Belgium.

Pauline Jen Ryan, Partner, Red Sky Partners

Pauline Jen Ryan

At Red Sky, Pauline Jen Ryan serves clients by taking on interim C-level roles (CEO, CBO, COO) or acting as an advisor on general corporate and business development matters. Her particular expertise is with small- to mid-size biotech companies, including startups and companies leveraging “virtual” operating models. Pauline has served as virtual CBO for several oncology companies. Most recently, Pauline served as interim co-CEO of Harbour Antibodies where she led the management of consultants/employees, started a US subsidiary and completed numerous business development transactions.

In addition to her work at Red Sky, Pauline is currently CEO of Verik Bio, a biotech startup pioneering T cell-based immunotherapy for solid tumor cancers. Prior to joining Red Sky Partners, Pauline helped lead investor Healthcare Ventures raise a $45M Series A round to launch Proteostasis Therapeutics. In addition to setting intellectual property and business development strategy, she was responsible for establishing and growing all business operations functions such as finance, human resources and communications from launch to 50 employees. Previously, Pauline was Senior Vice President, Corporate Development & Operations at ImmunoGen, where secured the corporate partnership with Genentech that created Kadcyla® for breast cancer. She headed corporate strategic planning, business development and alliance management during her tenure there and was also responsible for human resources, manufacturing, and program management during growth and transition stages. She was responsible for raising over $150M in corporate partnerships and was also instrumental in completing a $125M secondary offering.

Pauline is a member of The Boston Club and also volunteers as a Trustee of the Advanced Math and Science Academy Charter School, currently serving as Chair. She was previously a member of the Board of Directors for Lumio, a startup incubating at the Martin Trust Center for Entrepreneurship at MIT, and also for Solmap Pharmaceuticals (acquired by Forma Therapeutics). Pauline was also a founding member of the Biotechnology Industry Organization’s Business Development Advisory Committee and launched the BIO Business Development Fundamentals Course in 2003.

Pauline has an MBA from the Kellogg Graduate School of Management at Northwestern University, and a BA in Psychology from Northwestern University.

Kate Skrable, Director of Alliance Management, Genentech Partnering

Kate Scrabble

Kate Skrable has over 20+ years in business development and alliance management.  Kate approaches alliance management with dedication, leadership, and advocacy.  She has been with Genentech Partnering for over 6 years.  During her tenure she has managed dozens of research, development, and commercial partnerships and collaborations.  Prior to joining Genentech Partnering, Kate worked in a variety of licensing, alliance management, and mergers/acquisitions roles at Valeant, Perlegen, and Connetics.

Kate holds an MBA from Santa Clara University, a MS in Physiology from University of Arizona, and BS from Loyola Marymount University.  She is also a member of ASAP (Association of Strategic Alliance Professionals).

Wyatt Gotbetter, Partner, Health Advances

Wyatt Gotbetter

Wyatt helps lead Health Advances’ Biopharma practice and focuses on commercial growth and business development strategies for therapeutics and their convergence with med tech in Digital Health and Drug Delivery work.

Immediately prior to joining Health Advances, Wyatt worked at the Boston Consulting Group (BCG) where he advised global biopharma and medtech clients and led teams in growth and product launch strategies, M&A integration, and organizational optimization. He previously worked at Biogen as the Head of New Product Commercialization, developing clinical and commercial strategies for pipeline programs in neurology, immunology and oncology, while supporting corporate and business development activities. Earlier, at Boston Scientific Corporation, Wyatt created and led a new function to achieve market access with US commercial health plans, supporting launches across their portfolio and business units.

Wyatt earned his BS degree in Economics & Policy Analysis and an MPAdegree, including a certificate from the Sloan Graduate Program in Health Services Management, at Cornell University.

Robert Silverman, JD, PhD, Senior Vice President and General Counsel, Concert Pharmaceuticals, Inc. 

Robert Silverman

Robert Silverman, J.D., Ph.D. has served as Senior Vice President and General Counsel to Concert pharmaceuticals since December 2010 and prior to that was our Vice President and General Counsel from January 2007 to December 2010. Prior to joining Concert, he served in various legal related roles at Millennium Pharmaceuticals, Inc., a pharmaceutical company and Vertex Pharmaceuticals, a pharmaceutical company.   Dr. Silverman began his legal career at FMC Corporation, a chemical manufacturing company, where he was previously a research chemist.  

Dr. Silverman received his J.D. from Rutgers-Camden Law School.  He did postdoctoral research in organic chemistry at Stanford University after receiving a Ph.D. from the University of New Mexico and a B.A.. from Lehigh University.

Patricia Sinatra, Managing Director, Vector Strategic Advisors, Program Director, BIO Business Development Fundamental Courses

Patricia Sinatra

Patricia Sinatra has over 20 years of experience in the biopharmaceutical industry and has held various roles of increasing responsibility in both the commercialization and licensing of novel technologies used to treat human disease. She has worked with over 30 different companies in the Biopharma space, and has experience working with many first in class-based technologies and products. Pat has "hands-on" launch experience of novel therapeutics as well as strategic marketing and new product planning. She has developed and managed marketing campaigns, market research and developed strategies for many products. Pat also has more than 15 years of experience in the licensing function, and has negotiated or made pivotal contributions for over 15 transactions with big pharrma, biopharma and academic institutions. These include co-dev, technology licensing, and in-licensing type deals in addition to negotiating and amending agreements that were revenue driving. She has managed more than 10 revenue generating alliances. Since 2007, Pat has also instructed and organized the annual 3-day compehensive Business Development Fundamentals Course offered through the Biotechnology Industry Organization (BIO) and the Licensing Executives Society (LES). Pat graduated from the State University of New York where she holds a B.S. in biology with minor emphasis in chemistry and studio art, and pursued post-graduate studies in the department of microbiology at the University of Texas Southwestern Graduate School of Biomedical Sciences. She is also a dual citizen of the United States and Italy.

Ken Weber, PhD, Partner, Kilpatrick Townsend & Stockton LLP

Kenneth Weber

Kenneth Weber, Ph.D., focuses his practice on patent prosecution, particularly in the areas of molecular genetics, chemistry, pharmaceuticals, plant science, medical devices and microbial genetics. He regularly assists clients in patent portfolio management, due diligence reviews, validity/infringement opinions and licensing.

Dr. Weber's clients include public and private corporations across the United States. Representative corporate clients include Aqua Bounty Technologies; Avanir, Inc.; Biosensors International; and Corcept Therapeutics, Cepheid, Inc., Ciphergen Biosystems, Inc. and Sutro Biopharma based in California. Ken is a member of the American Bar Association and the American Intellectual Property Law Association. He received his J.D. degree from the University of Washington and holds a PhD in Plant Pathology.

 

 

2018 Agenda

Friday, June 1, 2018

7:30 AM - 8:30 AM Registration Open & Breakfast
8:30 AM - 10:00 AM Welcome and Introductory Remarks
Introduction to Strategic Alliances and Negotiation 
 
10:00 AM - 10:30 AM Networking Break
10:30 AM - 12:00 PM Strategic Alliances and Negotiation (continued)
12:00 PM - 1:00 PM   Networking Lunch
1:00 PM - 5:00 PM Intellectual Property 
5:00 PM - 7:00 PM Networking Reception

 

Saturday, June 2, 2018

7:30 AM -  8:30 AM Networking Breakfast
8:30 AM - 10:00 AM Finance Applications in Licensing
10:00 AM - 10:30 AM Networking Break
10:30 AM - 12:00 PM Finance Applications in Licensing (continued)
12:00PM - 1:00 PM Lunch
1:00 PM - 3:00 PM Contract Basics 
3:00 PM - 3:30 PM Networking Break
3:30 PM - 5:00 PM Contract Basics (continued)

 

Sunday, June 3, 2018

7:30 AM – 8:30 AM Networking Breakfast
8:30 AM - 10:00 AM Negotiation: Persuasion and Influence Strategies
10:00 AM - 10:30 AM Networking Break
10:30 AM - 12:00 PM Making the Deal Work: The Role of Alliance Management
12:00 PM - 1:00 PM Networking Lunch
1:00 PM - 2:30 PM The Role of the University In Creating Portfolio Value
2:30 PM - 5:00 PM Term Sheet Case Study/Wrap Up 

Conferences and Events: 

Product & Company Valuation Course

 

 

The Product & Company Valuation course is designed to teach a systematic approach to producing a valuation which can be used in investment rounds, mergers/acquisitions, licensing deals or strategic development decisions in the pharma-biotech world. It goes beyond the number-crunching techniques of most consultants and includes difficult to define qualitative factors which shape the risk profile of the company in question.

Valuation is an inherently subjective task which is made even more difficult in the life science industry due its unique challenges: high attrition rates in R&D, long investment cycle, complex technologies and IP situations, etc. Therefore, traditional valuation methods are not suitable. Of particular value in this course is the Product Valuation and Deal Structuring module where you will learn the commonly used rNPV (risk-adjusted Net Present Value) method for calculating the value of a drug in development. Subsequently, you will practice how to structure a licensing deal between companies. You will use an Excel-based tool designed specifically for this module (which can be taken home).


2018 Product and Valuation Course Instructor:

Patrik Frei, CEO & Founder, Venture Valuation

Patrik Frei

Patrik Frei is a leading expert in the valuation of life science companies and his combination of knowledge and experience allows him to speak with authority on the subject. Patrik wrote the first book on the valuation of high-growth companies and holds a Ph.D in the field. His company, Venture Valuation, has completed over 400 independent company and product valuations.

 

 

Topics Covered*:

  • Introduction to Valuation
  • Assessing a Company Prior to Valuation
  • Company Valuation and Methods
  • Product Valuation and Methods
  • Deal Structuring

Who should attend?

This is an introductory course and therefore very valuable for pharma and biotech executives who are not familiar with compound and company valuations but need a thorough understanding of the valuation concepts and techniques that are commonly applied in the pharma and biotech industries.

2018 Agenda

Sunday, June 3, 2018

10:00 AM - 10:15 AM Welcome
10:15 AM - 11:00 AM Introduction to Valuation: What – Why - When
11:00 AM - 11:30 AM How to Assess a Company Prior to Valuation
11:30 AM - 11:45 AM Break
11:45 AM - 1:30 PM Company Valuation
1:30 PM - 2:15 PM Lunch
2:15 PM - 4:45 PM Product Valuation & Deal Structuring
4:45 PM - 5:00 PM Final Discussion & Wrap-up

 

Conferences and Events: 

Registration Policies

  • Cancellations: Requests must be submitted in writing on or before May 10, 2018, (5:00 pm United States Eastern Daylight Time) to receive a partial refund. A $400 administrative fee will be deducted from all canceled refunds. Requests received after May 10, 2018, will NOT be honored and no course credit will be offered for future years. Substitutions are always accepted (see below) Email cancellation requests to convention@bio.org.
  • Substitutions: You may transfer your registration to another individual or make changes by sending your request to convention@bio.org no later than May 28, 2018 (5:00 pm United States Eastern Daylight Time)
  • A government-issued photo ID (driver’s license or passport) is required at check-in. Badges will not be issued without proper identification
  • Your company must be a BIO member in good standing on or before June 8, 2018 to receive the BIO member rate
  • There are no special organizational rates for the courses. The only rates offered are Member and nonmember rates.

 

Conferences and Events: 
H1: 
Executive Training Registration Policies

2018 Supporting Organizations

AUTM          

     

Conferences and Events: 
H1: 
2018 Supporting Organizations

Advanced Business Development Course

The Advanced Business Development Course is designed for executives and business development professionals interested in bringing their skills in valuation, deal structuring, due diligence, negotiation and contracts to the next level. During this intense, three-day workshop attendees will receive hands-on, advanced training from veteran business development professionals and legal advisers using real world case studies. In addition, attendees will be split into teams to conduct a mock negotiation over rights for a clinical stage compound.

The faculty is drawn from among the most experienced business development professionals in the biotech drug development industry as well as big pharma, many of whom have been instructors in other programs, and all of whom have hands-on experience in the biotech industry.


2018 Advanced Business Development Faculty:

Debbie Allen, Senior Vice President Business Development, arGEN-X

Debbie Allen

Debbie Allen has been active in the antibody engineering field since the 1980s. She brings to argenx more than 30 years of corporate and business development experience with small and large biotech companies focused on biopharmaceuticals. Dr. Allen is an inventor of HUMIRA® (adalimumab). She established her business development career at Cambridge Antibody Technology (acquired by Astra Zeneca), where she had management responsibility for technology, intellectual property and product out-licensing, corporate equity, co-development and cross-license agreements. She was responsible for the 1999 license agreement with Human Genome Sciences that led to the discovery of the antibody drug BENLYSTA®(belimumab), now approved for the treatment of systemic lupus erythematosus.

Prior to joining argenx, Dr. Allen acted as an independent consultant to around 25 emerging biotech companies, providing strategic management and business development support.

Joe Dillon, PhD, MBA, President, Dillon Capital Strategies

Dillon

Joseph S. Dillon, Ph.D., MBA, is President & CEO of SynerPhysics, Inc. and President of Dillon Capital Strategies, the strategy and business analytics advisory arm of SynerPhysics. Dr. Dillon is a seasoned pharmaceutical executive with over 20 years of experience. He has extensive experience in global pharmaceutical business development, planning and analysis, corporate finance, M&A, licensing, and technology valuations. Dr. Dillon has screened thousands of opportunities, valued over 300 deals and has been involved in over 40 closed transactions over the course of his career. Since forming Dillon Capital Strategies, Dr. Dillon has consulted dozens of companies, including holding the CEO position at BioPact, a medical nanotechnology company, during its developmental stage. Prior to that, Dr. Dillon held senior positions in pharmaceutical management consulting firms, most significantly as Senior Vice President, Head of Corporate Development Services and Valuations for The Mattson Jack Group (now Kantar Health). Other previous positions include CEO, President, and Director of The Pharmaceutical Development Center, a pharmaceutical developer and manufacturer; Executive Vice President and CFO of Vail Banks Inc., a multi-bank holding company; CFO and Treasurer of Oread Inc., a contract pharmaceutical developer and manufacturer; and corporate positions with predecessor companies of Sanofi. Dr. Dillon is Past-Chairperson of the Licensing Executive Society Life Sciences Sector. He is a veteran speaker at BIO, LES, WBR, EBD, and other prominent industry organization events. Dr. Dillon holds a Ph.D. in Metaphysical Sciences, an M.B.A. in International Finance and a bachelors in Finance.

Luke Kempton, PhD, Partner, Gowling WLG

Luke Kempton

Luke leads Gowling WLG's IP Transactional team. With a PhD in Biochemistry, it’s no surprise that Luke’s main focus is the life sciences, a sector he’s been active in for over 20 years, advising on transactions for Big Pharma, small biotech companies and research institutions. Luke also has particular experience of working with European, Japanese and Chinese life sciences companies and his experience covers drafting and negotiating licences, collaboration agreements, product acquisition agreements, clinical trial agreements, and pharma manufacturing agreements. His clients include Astellas, Bial, Eisai, EUSA Pharma, K.U. Leuven, Kyowa Hakko Kirin, Tusk Therapeutics and VIB.

Luke was recognised as a 'patent star' in the IP Stars guide 2017. He is also is recommended by Chambers UK for intellectual property and life sciences: transactional, and by The Legal 500 for intellectual property.

Kenneth Krisko, Partner, Cooley LLP

Kenneth Krisko

Kenneth Krisko is a partner in the Cooley Business department. He joined the Firm in 2000 and splits his time between the Reston and Boston offices.

Mr. Krisko's practice focuses on the representation of public and private life sciences companies in a broad range of commercial and corporate finance matters. He advises clients regularly with respect to complex commercial transactions designed to maximize the value of pharmaceutical products and technology assets, including technology licenses and acquisitions, research and development collaborations, distribution and manufacturing agreements, and profit-sharing and co-promotion arrangements.

Mr. Krisko also regularly counsels clients on a wide array of corporate and securities matters, including spin-outs, private financing, mergers and acquisitions, public offerings and corporate governance. He works closely with his clients to understand each client's business and strategic objectives and to structure and negotiate transactions to meet those objectives.

Mr. Krisko has been a guest speaker on strategic partnering and corporate issues affecting life sciences companies at various conferences. Mr. Krisko also is an Adjunct Professor of Law at the Georgetown University Law Center where he teaches a course on emerging company legal issues and venture capital finance.

Mr. Krisko received a JD from the University of Virginia School of Law in 1995, where he was a member of the Virginia Law Review. Mr. Krisko received a BS in Aerospace and Ocean Engineering from Virginia Tech in 1987.

Prior to joining Cooley, Mr. Krisko was an associate with Wiley, Rein & Fielding in Washington, DC  Prior to attending law school, Mr. Krisko worked as an engineer for the Department of the Navy.

Mr. Krisko is admitted to practice in the Commonwealth of Virginia, the District of Columbia. He is not admitted to practice in Massachusetts.

Lesley Stolz, PhD, Head of JLABS California

Lesley Stolz

Lesley is Senior Director of Transactions at Johnson & Johnson Innovation, California. Lesley has been working in corporate and business development roles for the last 17 years for companies that are both technology platform and therapeutics focused; Her most recent executive positions have been with BioTime, a publicly traded stem cell technology and therapeutic company, and Sutro Biopharma, a platform technology company working in cell-free protein synthesis. Prior to Sutro, Lesley served in BD positions for a number of biotech companies in the U.S.. and Europe. Lesley received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School’s Department of Biochemistry and Molecular Pharmacology.

Topics Covered*:

  • Valuation and Deal Structuring Concepts and Trends
  • Advanced Valuation and Decision Analysis
  • Select Topics of Advanced Deal Structures
  • Market Models, Competition, Cash Flow Estimates
  • Case Study Work
  • Value Distribution and Terms
  • Key Concepts and Building Blocks of a Block Buster Deal
  • Trap Doors, Dead Ends, and Other Do's and Don'ts
  • Current Trends in Licensing Deals

Who should attend?

It is designed for business development professionals who have most likely served as part of a business development or licensing team, but are now preparing to move to a senior manager level role within their organization. Highly experienced business development professionals benefit by getting an update on the latest techniques, revised rules/regulations and honing deal-making skills.

  • Business development & licensing professionals
  • Alliance management professionals
  • R&D personnel who have significant interaction with business development
  • Intellectual property personnel involved in the licensing process
  • Biotech company CEOs
  • Professionals who are new to business development and licensing or who have limited deal experience

2018 Agenda

Friday, June 1, 2018: Valuation and Deal Structuring Skills

7:00 AM - 8:30 AM Registration Open & Breakfast
8:30 AM - 9:45 AM Valuation and Deals Structuring Concepts and Trends
9:45 AM - 10:00 AM Refreshment Break
10:00 AM - 11:00 AM Advanced Valuation and Decision Analysis
11:00 AM - 12:30 PM   Case Study Work
12:30 PM - 1:30 PM   Lunch
1:30 PM - 2:30 PM Market Models, Competition, Cash Flow Estimates
2:30 PM -2:45 PM Refreshment Break
2:45 PM - 4:00 PM Case Study Work & Break Out Sessions
4:00 PM - 5:00 PM Value Distribution and Terms
5:30 PM - 7:00 PM Networking Reception

 

Saturday, June 2, 2018: Negotiation Strategies and Intellectual Property

7:30 AM -8:30 AM Breakfast
8:30 AM - 9:45 AM Negotiation Preparation
9:45 AM - 10:45 AM Case Study Work
Refreshments Available
10:45 AM - 11:45 AM Managing the Process and Influence Strategies
11:45 AM - 12:30 PM Case Study Work
12:30 PM - 1:30 PM Lunch
1:30 PM -3:00 PM Types of IP, Freedom to Operate, Issues in Due Diligence
3:00 PM - 4:15 PM Case Study Work 
Refreshments Available
4:15 PM - 5:00 PM Creating a Protection Timeline, Research Exemption, Competition Law
5:00 PM - 5:45 PM Case Study Work

 

Sunday, June 3, 2018: Contracts

7:30 AM - 8:30 AM   Breakfast
8:30 AM - 9:45 AM Key Concepts and Building Blocks of a Block Buster Deal
9:45 AM - 10:30 AM Select Topics of Advanced Deal Structures
10:30 AM - 10:45 AM Refreshment Break
10:45 AM - 11:45 AM Trap Doors, Dead Ends, and other Do's and Don'ts
11:45 AM - 12:30 PM Current Trends in Licensing Deals
12:30 PM -3:00 PM Working Lunch and Case Study Completion
3:00 PM - 3:45 PM Case Study Review
Conferences and Events: 

Business Development Fundamentals Course

Room 206AB, Level 2
Boston Convention Center

The Business Development Fundamentals Course is offered as a continuing education program for biopharmaceutical, academic and not for profit professionals as part of BIO’s executive training course series. The three-day course is instructed by experts in the areas of finance, transactional and intellectual property law, licensing and alliance management, management consulting and strategic commercial development.  The majority have held positions of increasing responsibility in the life sciences industry ranging from biotherapeutics to diagnostics and medical devices.

Friday, June 1, 2018

8:00 AM - 9:00 AM Registration Open & Breakfast
9:15 AM - 9:30 AM Introductory Remarks
9:30 AM - 10:30 AM Introduction to Intellectual Property    
10:30 AM - 10:45 AM Break
10:45 AM - 12:00 PM Introduction to Intellectual Property (continued)
12:00 PM - 1:00 PM Lunch
1:00 PM - 1:30 PM Technology Licensing and Strategic Alliances 
3:00 PM - 3:30 PM Networking Break
3:30 PM - 5:00 PM Technology Licensing and Strategic Alliances (continued)
5:30 PM - 7:00 PM Networking Reception   

 

Saturday, June 2, 2018

8:00 AM - 9:00 AM Registration Open & Breakfast
9:00 AM - 10:00 AM Finance Concepts in Licensing
10:00 AM - 10:30 AM Networking Break
10:30 AM - 12:00 PM Finance Concepts in Licensing (continued)
12:00PM - 1:00 PM Lunch
1:00 PM - 3:00 PM Contract Basics 
3:00 PM - 3:30 PM Networking Break
3:30 PM - 5:00 PM Contract Basics (continued)

 

Sunday, June 3, 2018

8:00 AM - 9:00 AM Registration Open & Breakfast
9:00 AM - 10:00 AM Negotiation Strategies
10:00 AM - 10:30 AM Networking Break
10:30 AM - 12:00 PM Negotiation Strategies (continued)
12:00 PM - 1:00 PM Lunch
1:00 PM - 2:30 PM The Role of the University Technology Transfer 
2:30 PM - 5:00 PM Case Study

 

2018 Business Development Fundamentals Faculty:

Anjan Aralihalli, Chief Business Officer, GLyPharma Therapeutic; Venture Partner, CTI Life Sciences Fund II

Anjan Aralihalli

Anjan or "AJ" Aralihalli is currently Chief Business Officer of GLyPharma Therapeutic, a Canadian biotechnology company focused on rare GI disorders.  He is also a Venture Partner at CTI Life Sciences, a leading Canadian venture fund and is a member of a NYC based angel investment group called Mid-Atlantic Bio Angels (MABA).  AJ is also a corporate fundraiser for two ALS charities, Wings Over Wall Street (a division of the Muscular Dystrophy Association) and The Robert Packard Center for ALS Research at Johns Hopkins University.

Previously, he worked at a variety of biotechs and pharma companies including Neurochem, Abbott, Sanofi, Shionogi and ActoGeniX.  He has 20+ years of international experience across a number of functions including investor relations, corporate development, venture and angel financing, in & out-licensing, strategic alliances, alliance management, new product development, sales, marketing, & clinical trial management.  

He received his BSc from Concordia University, MBA from Queen's University (both in Canada) and is currently completing his MSc at Johns Hopkins University.

Mark Cooper, Of Counsel, Faber Daeufer & Itrato PC

Mark Cooper

Mark is an accomplished and versatile corporate and transactional attorney in the life sciences industry with over 25 years of experience. Mark has extensive experience advising, structuring, drafting and negotiating strategic transactions (research, development and commercialization) at all stages of the product lifecycle, most recently at Faber Daeufer & Itrato PC and before, in-house at Pfizer.

During his 17 years with Pfizer, Mark structured and negotiated a wide range of complex research collaborations, IP licenses, development funding agreements and commercial stage co-promotion agreements. His experience with transactions at all phases of the pharmaceutical product life cycle has given him a deep understanding of business strategies and issues, including those involved with emerging technologies like gene therapy and RNAi.

Kathleen Denis, PhD, CLP-Founding Director, Office of Technology Transfer, The Rockefeller University

Kathleen Davis

Kathleen A. Denis, Ph.D. is the Associate Vice President of Technology Transfer at The Rockefeller University, a premier biomedical research institution located in New York City. Managing the intellectual assets of the University, she works with their elite group of researchers to establish partnerships with industry in order to develop and commercialize technologies for the public good. Formerly a consultant specializing in the management of intellectual assets in the life sciences, she worked with academic and industry clients to manage intellectual property portfolios, evaluate new technologies, market and license technologies and start new technology-based businesses.

Dr. Denis is active in numerous professional organizations and speaks frequently about early stage technology evaluation, formation of start-up companies, conflict of interest and other issues of academic technology transfer. She is a Past President of the Licensing Executives Society USA/Canada (LES), and has served on the Board of Directors of the Association of University Technology Managers (AUTM) and the Pennsylvania Biotechnology Association.

From 1995 through 1998 Dr. Denis was Vice President, Technology Development at Allegheny Health, Education and Research Foundation. She managed the intellectual property and research assets of the Medical College of Pennsylvania and Hahnemann University, as well as Allegheny General Hospital and Allegheny Singer Research Institute. Responsibilities of this position included the evaluation and marketing of technologies, building collaborative relationships with the biomedical and biopharmaceutical communities and promotion of economic development in Pennsylvania.

Dr. Denis was a Director at the University of Pennsylvania Center for Technology Transfer from 1991 to 1995, where she managed a large portfolio of biotechnology and pharmaceutical related technologies. Previously, she was an investigator at the Molecular Biology Institute at UCLA for eight years, and a Senior Scientist at Specialty Laboratories, Inc. She has over thirty scientific publications.

Dr. Denis holds a Ph.D. in immunology from the University of Pennsylvania, an M.A. in Human Genetics from University of Texas Medical Branch at Galveston and an undergraduate degree in genetics from Cornell University.

Philippe Nore, Co-founder and CEO, MiNDERA Dx

Phillippe Nore

Philippe Nore is an experienced executive specialized in clinical diagnostics, genomics and life science tools. He currently is CEO and co-founder of MiNDERA, an early stage clinical diagnostics company. Before founding MiNDERA, Philippe Nore was Senior International Business Leader at Roche Diagnostics. He was responsible for the development and commercialization of the Ventana Digital Pathology products (hardware, software, algorithms to score assays) in the cancer diagnostics market, including global P&L responsibility. During his tenure at Roche he has successfully launched several FDA-approved products.

Prior to that, he was a Senior Engagement Manager at L.E.K. Consulting where he worked with CEOs of small and midsize biotech and life sciences companies. Earlier, he worked at Life Technologies where he headed Strategic Planning and Business Development for the DNA Sequencing business Unit and led the Next-Generation Sequencing taskforce. He also spent 7 years at Bain & Company where he consulted for Fortune 500 companies.

Philippe has negotiated numerous licensing and acquisition transactions in his career and has deep expertise in strategic and financial valuation of biotech assets.

Philippe holds a MSc. in chemistry from ESPCI (Paris) and an MBA from the Wharton School where he graduated as a Palmer Scholar.

Pauline Jen Ryan, Partner, Red Sky Partners

Pauline Jen Ryan

At Red Sky, Pauline Jen Ryan serves clients by taking on interim C-level roles (CEO, CBO, COO) or acting as an advisor on general corporate and business development matters. Her particular expertise is with small- to mid-size biotech companies, including startups and companies leveraging “virtual” operating models. Pauline has served as virtual CBO for several oncology companies. Most recently, Pauline served as interim co-CEO of Harbour Antibodies where she led the management of consultants/employees, started a US subsidiary and completed numerous business development transactions.

In addition to her work at Red Sky, Pauline is currently CEO of Verik Bio, a biotech startup pioneering T cell-based immunotherapy for solid tumor cancers. Prior to joining Red Sky Partners, Pauline helped lead investor Healthcare Ventures raise a $45M Series A round to launch Proteostasis Therapeutics. In addition to setting intellectual property and business development strategy, she was responsible for establishing and growing all business operations functions such as finance, human resources and communications from launch to 50 employees. Previously, Pauline was Senior Vice President, Corporate Development & Operations at ImmunoGen, where secured the corporate partnership with Genentech that created Kadcyla® for breast cancer. She headed corporate strategic planning, business development and alliance management during her tenure there and was also responsible for human resources, manufacturing, and program management during growth and transition stages. She was responsible for raising over $150M in corporate partnerships and was also instrumental in completing a $125M secondary offering.

Pauline is a member of The Boston Club and also volunteers as a Trustee of the Advanced Math and Science Academy Charter School, currently serving as Chair. She was previously a member of the Board of Directors for Lumio, a startup incubating at the Martin Trust Center for Entrepreneurship at MIT, and also for Solmap Pharmaceuticals (acquired by Forma Therapeutics). Pauline was also a founding member of the Biotechnology Industry Organization’s Business Development Advisory Committee and launched the BIO Business Development Fundamentals Course in 2003.

Pauline has an MBA from the Kellogg Graduate School of Management at Northwestern University, and a BA in Psychology from Northwestern University.

Kate Scrable, Director of Alliance Management, Genentech Partnering

Kate Scrabble

Kate Skrable has over 20+ years in business development and alliance management.  Kate approaches alliance management with dedication, leadership, and advocacy.  She has been with Genentech Partnering for over 6 years.  During her tenure she has managed dozens of research, development, and commercial partnerships and collaborations.  Prior to joining Genentech Partnering, Kate worked in a variety of licensing, alliance management, and mergers/acquisitions roles at Valeant, Perlegen, and Connetics.

Kate holds an MBA from Santa Clara University, a MS in Physiology from University of Arizona, and BS from Loyola Marymount University.  She is also a member of ASAP (Association of Strategic Alliance Professionals).

John Selig, Managing Partner, WaveEdge Capital LLC

John Selig

John Selig is a Managing Partner and co-founder of WaveEdge Capital LLC, a healthcare investment bank advising companies on M&A, licensing and finance strategy. He was formerly Managing Director and co-head of the Life Sciences Group at Woodside Capital Partners.

Prior to joining Woodside, he was a Partner at Keelin Reeds Partners, a life sciences management consulting firm, where he advised dozens of VC-backed and small cap biopharmaceutical, medical device and diagnostics companies on M&A and licensing strategies, portfolio management, valuation and strategic direction. While at KR, John led a partnership deal term benchmarking effort and has extensive experience in applying that data to yield market-value deal terms for dozens of assets, using the results to inform product strategy and to provide ongoing support during deal negotiations. John also combined his expertise in valuation, deal term benchmarking and decision analysis with his background in law to help companies make optimal decisions in litigation and settlement.

Previously, John was a senior consultant with Strategic Decisions Group, a global management consulting firm, where he advised numerous Fortune 500 companies in life sciences and other industries on valuation, business strategy and M&A. Prior to consulting, John was an attorney with Weil, Gotshal & Manges LLP where he focused on M&A and corporate finance.

John holds a JD from Stanford Law School and a BA from Brown University.

Robert Silverman, Senior Vice President and General Counsel, Concert Pharmaceuticals

Robert Silverman

Kyle E. Murphy is the Managing Director and Founder of KMG Japan. Kyle has lived in Japan for a significant portion of his adult life. His business has involved working with Japanese and Asian Life Science and healthcare businesses for over 30 years. Kyle speaks Japanese and built a strong network of contacts in both the healthcare industry and government administration. He has represented over 100 clients and successfully structured numerous alliances between Japanese, Asian and foreign companies. Prior to founding KMG Japan, Kyle served as the First Commercial Secretary in the US Embassy in Tokyo where he managed all trade negotiations and activities related to bringing US companies into the Japanese healthcare market. Kyle began his career in the healthcare industry with business development and marketing positions at Schering-Plough in Osaka, Japan and SmithKline in the US.

Patricia Sinatra, Managing Director, Vector Strategic Advisors, Program Director, BIO Business Development Fundamental Courses

Patricia Sinatra

Ms Sinatra has directed and instructed the BIO BD Fundamentals course since 2007.  She is also Chair of the Next Generation Biotherapeutics Educational Session for the 2018 BIO meeting.  She possesses more than 20 years of biopharmaceuticals industry experience where her expertise blends licensing, alliance management with a foundation in strategic marketing, corporate and technology positioning and market research. She has negotiated a variety of deal structures with big pharma, biotech and academia. She is currently Managing Director of Vector Strategic Advisors LLC. Previously, she held senior business development, marketing, and strategy positions for Telomere Diagnostics, Sutro Biopharma (previously Fundamental Applied Biology), Dynavax Technologies, Abgenix (Amgen), Matrix (Novartis), SEQUUS/ALZA (JNJ), FCB Healthcare and Smithkline Beecham (GSK). She is also an advisor for the UCSF Start Up 101 and the California Life Science Institute’s FAST programs.

Earlier in her career she was a Visiting Assistant Professor of Biology at the University of Dallas and taught a continuing education module for physicians and nurses for the Department of Health in Dallas, TX.   Ms. Sinatra  received her undergraduate degree from the State University of New York and conducted PhD studies in Microbiology at the University of Texas Southwestern Graduate School of Biomedical Sciences. She has also conducted extensive continuing education courses in marketing, finance and accounting at UC Berkeley. 

Ken Weber, PhD, Partner, Kilpatrick Townsend & Stockton LLP

Kenneth Weber

Kenneth Weber, Ph.D., focuses his practice on patent prosecution, particularly in the areas of molecular genetics, chemistry, pharmaceuticals, plant science, medical devices and microbial genetics. He regularly assists clients in patent portfolio management, due diligence reviews, validity/infringement opinions and licensing.

Dr. Weber's clients include public and private corporations across the United States. Representative corporate clients include Aqua Bounty Technologies; Avanir, Inc.; Biosensors International; and Corcept Therapeutics, Cepheid, Inc., Ciphergen Biosystems, Inc. and Sutro Biopharma based in California. Ken is a member of the American Bar Association and the American Intellectual Property Law Association. He received his J.D. degree from the University of Washington and holds a PhD in Plant Pathology.

Course Objectives:

The goal of the course is to provide an intensive and comprehensive educational foundation on the core skills that are needed to be a successful licensing executive in the life sciences industry and a networking platform for attendees.

Topics Covered*:

  • The Role of Intellectual Property In Creating Value
  • Strategic Alliances - Partner and technology opportunity assessment and process, types of deal structures, term sheet development, the role of alliance management
  • Financial Modeling and Valuation in Licensing
  • Contracts Used in Licensing  (CDAs, MTAs, Sponsored Research Agreements, Definitive Agreements )
  • Negotiation and Communication Strategies
  • University Technology Transfer and it’s Role in IP Creation 
  • Case Study

Who should attend?

  • Professionals who are new to business development and licensing or who have limited deal experience.
  • Alliance management, R&D, legal, marketing or academic professionals who desire to learn more about licensing within their organizations or as a career opportunity.
  • Entrepreneurs who have not been exposed to licensing or M&A type transactions but recognize it as a critical strategic initiative for their business.
  • Professionals interested in a comprehensive refresher course in licensing.

Fees:

BIO Member $1,920
Non-Member $2,400

 

If you have any questions about the program, please contact Patricia Sinatra at psinatra221@gmail.com.

*Content is subject to modification.

 

Conferences and Events: